Connectoma Neurotech shared testimonial from patient Sergio Díez who experienced a resistant depression with cognitive and emotional impairments after TMS therapy.
Public source
Publisher name
Public post
Hoy compartimos el valioso testimonio de Sergio Díez, paciente de Connectoma. Sergio relata cómo se vive en primera persona una "depresión resistente", un cuadro clínico…
Company
Connectoma Neurotech
Reshaping the healing process of mental illness.
- Industry
- Mental Health Care
- Location
- Madrid, ES
- Company size
- 2–10 employees
About Connectoma Neurotech
At Connectoma, we're revolutionizing mental health care with advanced AI and neurotechnology solutions. By mapping individual neural connections through AI-driven fMRI analysis, we provide precise diagnoses and personalized transcranial magnetic stimulation (TMS) treatments for complex conditions such as treatment-resistant depression, PTSD, chronic pain, and addictions. Join us in transforming lives and redefining the future of mental wellness. Why Connectoma? - Cutting-Edge Technology: Leveraging AI-driven fMRI analysis to understand the unique neural pathways of each individual. - Personalized Treatments: Delivering tailored TMS therapies that address specific mental health challenges effectively. - Impactful Results: Aiming to improve outcomes for those suffering from the most resistant and challenging mental health conditions. Be part of the revolution in mental health care. Together, we're reshaping lives and pioneering a new future for mental wellness.
See moreLatest activity
Latest activity from Connectoma Neurotech
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Customers & Market
Spring Health
Spring Health reported that 92% of its members reliably improved or recovered from depression or anxiety, with members recover 5.9 weeks faster than with the leading competitor.
Customers & Market
Brightside Health
Brightside Health reported that 77% of program members no longer had suicidal thoughts within 12 weeks.
Products & Services
Marpa Minds
Marpa Minds offers Spravato, an FDA-approved option acting on glutamatergic signaling rather than monoaminergic pathways for treatment-resistant depression when used alongside an oral antidepressant.
Customers & Market
Two Chairs
Two Chairs reported that 79% of its clients achieved clinically significant improvement in anxiety and depression through measurement-based care, therapist-client matching, and clinical support.
Customers & Market
Kana Health Inc.